imatinib mesylate has been researched along with Hematologic Diseases in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bekir, L; Braham, N; Ghariani, I; Hamzaoui, S; Mahmoud, O | 1 |
| Bi, C; Jin, L; Li, J; Lv, Y; Pan, P; Shen, L; Sun, C; Sun, M; Wang, L; Wang, Y; Xue, Z; Yao, Y; Zhang, A; Zheng, P | 1 |
| Cortes, JE; DeGutis, I; Gajavelli, S; Gambacorti-Passerini, C; Goldberg, SL; Hehlmann, R; Mauro, MJ; Michallet, M; Paquette, RL; Sen, GP; Simonsson, B; Williams, LA; Zyczynski, T | 1 |
| Ammerlaan, RA; Chu, IW; Cornelissen, JJ; Deenik, W; Falkenburg, JH; Janssen, JJ; Kersten, MJ; Ossenkoppele, GJ; Schattenberg, A; Schipperus, M; Sinnige, HA; Smit, WM; Sonneveld, P; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE | 1 |
| Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Cogan, E; Roufosse, F | 1 |
| de Revel, T; Fagot, T; Konopacki, J; Malfuson, JV; Mangouka, L; Souleau, B | 1 |
| Cortés, JE; Kantarjian, H; Quintás-Cardama, A | 1 |
| Bradley-Garelik, MB; Cortes, J; DiPersio, J; Dorlhiac-Llacer, P; Kantarjian, H; Khoroshko, N; Khoury, HJ; Kim, DW; Müller, MC; Pasquini, R; Radich, JP; Tallman, MS; Zhu, C | 1 |
| Alimena, G; Breccia, M; Cannella, L; Diverio, D; Federico, V; Latagliata, R; Nanni, M; Santopietro, M; Stefanizzi, C | 1 |
| Schiffer, CA; Zonder, JA | 1 |
| Arellano, M; Assouline, S; Bernal-Mizrachi, L; Cortes, J; Khoury, HJ; Lima, LM; McLemore, M; Nault, S; Sampat, K; Saxe, D; Tighiouart, M; Winton, E | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, K; Kobayashi, Y; Miyawaki, S; Motoji, T; Nagai, T; Ohno, R; Okada, M; Sakamaki, H; Seriu, T; Taniwaki, M; Uoshima, N; Usui, N; Yamamoto, K | 1 |
| Block, AW; Vigil, C; Wetzler, M | 1 |
| Cashen, A; DiPersio, JF; Khoury, H | 1 |
| Abruzzese, E; Amadori, S; Anemona, L; Campione, E; Cantonetti, M; Del Principe, MI; Masi, M; Morino, L; Orlandi, A; Orlandi, G; Tendas, A | 1 |
| Scheinfeld, N; Schienfeld, N | 1 |
| Baltathakis, I; Harhalakis, N; Karakasis, D; Manola, KN; Pantelias, GE; Rigana, H; Sambani, C; Stamouli, MI; Stavropoulou, C; Symeonidis, A; Tiniakou, M; Zoumbos, N | 1 |
| Countouriotis, A; Moore, TB; Sakamoto, KM | 1 |
6 review(s) available for imatinib mesylate and Hematologic Diseases
| Article | Year |
|---|---|
Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2020 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles | 2006 |
A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Topics: Animals; Benzamides; Dermatofibrosarcoma; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Skin Neoplasms | 2006 |
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Surface; Antineoplastic Agents; Benzamides; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia; Leukocyte Common Antigens; Lymphoma, B-Cell; Piperazines; Pyrimidines; Rituximab; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
3 trial(s) available for imatinib mesylate and Hematologic Diseases
| Article | Year |
|---|---|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Treatment Outcome; Young Adult | 2013 |
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure | 2016 |
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Genes, abl; Heart Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
11 other study(ies) available for imatinib mesylate and Hematologic Diseases
| Article | Year |
|---|---|
Hematological hypereosinophilia
Topics: Female; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies | 2022 |
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Topics: Aged; Antineoplastic Agents; Dasatinib; Disease Management; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Substitution; Europe; Female; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Molecular Targeted Therapy; Musculoskeletal Diseases; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Respiratory Tract Diseases; United States | 2019 |
[Practical approach to hypereosinophilia].
Topics: Benzamides; Eosinophils; Food Hypersensitivity; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Mutation; Neoplasms; Parasitic Diseases; Piperazines; Prednisone; Protein-Tyrosine Kinases; Pulmonary Eosinophilia; Pyrimidines | 2008 |
[Hematological disorders and hypereosinophilias].
Topics: Antineoplastic Agents; Benzamides; Eosinophilia; Gene Rearrangement; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2009 |
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; Treatment Outcome | 2010 |
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins v-abl; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2011 |
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2011 |
The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome.
Topics: Benzamides; Female; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2011 |
Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2003 |
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
Topics: Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Chromosome Aberrations; Cytogenetic Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Skin Neoplasms | 2003 |
Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation.
Topics: Adult; Antiviral Agents; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 9; Cytomegalovirus Infections; Ganciclovir; Hematologic Diseases; Hematopoiesis; Humans; Imatinib Mesylate; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recovery of Function; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2006 |